When to Try Biologics for Ulcerative Colitis: An Expert Explains

Ulcerative colitis (UC) has a special talent: it can make a perfectly normal day revolve around bathrooms, fatigue, and
the kind of abdominal drama that deserves its own reality show. The good news is that modern treatment isn’t limited to
“hope, prayers, and bland toast.” If you’ve been hearing more about biologics for ulcerative colitis,
you’re not aloneand you’re not “failing” anything by needing them.

So, when should you try biologics for ulcerative colitis? Think of biologics as targeted “volume knobs”
for the immune system. They’re often used for moderate to severe UC, steroid-dependent disease, or when
other meds aren’t getting you to the real goal: not just fewer symptoms, but deep remission
(including healing seen on a scope).

This article breaks down the decision the way many IBD specialists think about it: risk, response, and real life. Not
medical advicemore like an expert’s map so your next appointment feels less like a pop quiz.

First, a quick UC treatment reality check

UC treatment is often described as a “step-up” approach: start with simpler meds, then escalate if needed. But modern UC
care is less like a ladder and more like a GPS that reroutes based on how your disease behaves.

Common treatment buckets (simplified)

• 5-ASA (mesalamine): often for mild to moderate UC, especially left-sided disease.
• Corticosteroids: good at putting out fires, terrible as a long-term roommate.
• Immunomodulators (like thiopurines): sometimes used for maintenance, but less favored as solo “big guns” today.
• Advanced therapies: biologics and certain targeted oral meds (small molecules) used for moderate to severe disease.

Here’s the key mindset shift: the goal isn’t “Can you survive this flare?” It’s “Can we prevent the next one and protect
your colon long-term?”

What biologics are (and what they aren’t)

Biologics are lab-made antibodies that target specific immune pathways driving inflammation. In UC, biologics are commonly
used to induce remission (calm things down) and maintain remission (keep it calm).

Main biologic classes used in ulcerative colitis

• Anti-TNF agents (block tumor necrosis factor):
  infliximab, adalimumab, golimumab.
• Anti-integrin (gut-selective “traffic control”):
  vedolizumab.
• Interleukin pathway biologics:
  ustekinumab (IL-12/23) and newer IL-23–targeting options such as mirikizumab, guselkumab, and risankizumab.

Biologics aren’t painkillers, probiotics, or a new personality for your colon (though wouldn’t that be nice?). They’re
immune-targeted therapies designed to reduce inflammation in a measurable, trackable way.

When to try biologics for ulcerative colitis

Clinicians usually recommend biologics when UC is more than “annoying.” That can mean symptoms, objective inflammation,
complications, or a pattern that suggests the disease is likely to stay active unless you change strategy.

1) Your UC is moderate to severe (not just “having a bad week”)

If you’re having frequent diarrhea, bleeding, urgency, nighttime symptoms, significant fatigue, or weight lossespecially
if it’s limiting work, school, parenting, or sleepbiologics move from “someday” to “let’s talk now.”

Severity is also confirmed by tests: colonoscopy/sigmoidoscopy findings (like ulcers), elevated inflammatory markers, or
imaging/labs showing active disease.

2) You keep needing steroidsor can’t get off them

Steroids can be a lifesaver for short-term flares. But if you’re doing the prednisone tango repeatedly (“start, taper,
relapse, repeat”), that’s a red flag. Steroid dependence is one of the clearest signs you need a maintenance plan that
actually maintains.

Many experts view steroids as a bridge, not a destination. If you need them more than once, or you flare during a taper,
it’s reasonable to discuss biologics or other advanced therapies.

3) Your scope still shows inflammation (even if you “feel okay-ish”)

UC can be sneaky: symptoms can improve while inflammation lingers. Modern care often aims for treat-to-target:
symptom control and mucosal healing, because healing is linked with better long-term outcomes.

If your colonoscopy shows moderate/severe inflammation, deep ulcers, or widespread disease, many gastroenterologists will
escalate earlier rather than “wait and see” while your colon stays irritated.

4) You have high-risk features that predict a tougher course

Not all UC is equally “stubborn.” High-risk patterns often push the decision toward earlier biologics, including:

• Extensive colitis (inflammation beyond the left side of the colon)
• Deep ulcerations on endoscopy
• High inflammatory markers (depending on your baseline)
• Hospitalization for severe flares
• Early need for steroids, or steroid-refractory disease
• Significant impact on nutrition, growth (in younger patients), or quality of life

5) You’ve tried appropriate first-line therapies and they’re not enough

For many people, mesalamine works wellespecially in mild to moderate UC. But if you’ve done the “right” regimen and still
have bleeding, urgency, or objective inflammation, it may be time to move beyond 5-ASA and talk advanced therapy options.

6) You have extraintestinal manifestations (your UC has left the building)

UC isn’t always polite enough to stay in the colon. Some people develop joint pain/arthritis, skin issues (like erythema
nodosum), eye inflammation (uveitis), or other immune-related problems. Certain biologics can help treat both intestinal
and extraintestinal inflammation, which may influence therapy choice.

7) You’re facing (or recovering from) acute severe ulcerative colitis

If UC becomes severe enough to require hospitalization, treatment decisions become more urgent. In steroid-refractory cases,
biologic “rescue therapy” (often with infliximab) may be considered to avoid complications and, in some cases, surgery.

Step-up vs. “top-down”: why timing matters

The classic step-up model starts with milder meds and escalates. A more modern, risk-based model asks:
“Is this the kind of UC that’s likely to stay mild, or the kind that likes to set the calendar on fire?”

If you have high-risk features, repeated steroid use, or significant endoscopic disease, many specialists will recommend
biologics sooner to prevent ongoing inflammation and reduce the chance of complications. This isn’t “aggressive for the
sake of aggressive.” It’s preventativelike fixing a leaky roof before you start naming the mold.

How doctors choose which biologic to start

There’s no single “best biologic for everyone.” The best choice is the one that fits your disease pattern, prior medication
exposure, safety considerations, lifestyle, and access/insurance reality.

Anti-TNF (infliximab, adalimumab, golimumab)

Anti-TNFs are widely used and can be very effective, especially when rapid control is needed. Infliximab, in particular,
is commonly used in more severe presentations and in hospitalized rescue settings. Some patients benefit from combination
therapy (anti-TNF plus an immunomodulator) to reduce antibody formation and improve durability.

Gut-selective option (vedolizumab)

Vedolizumab targets immune cell “homing” to the gut and is often described as gut-selective. For many patientsespecially
those concerned about systemic immune suppressionthis profile can be appealing. It may take a bit longer to reach full
effect in some people, but it’s a strong option for induction and maintenance.

Interleukin pathway biologics (ustekinumab and IL-23 inhibitors)

Ustekinumab targets IL-12/23 signaling. Newer IL-23–targeting biologics (including mirikizumab, guselkumab, and risankizumab)
expand the toolkit for moderate to severe UC, including for people who didn’t respond well to older biologics.

Practical factors that matter more than you’d think

• Route: infusion center vs. self-injection at home.
• Speed: how quickly control is needed.
• Safety profile: history of infections, other immune conditions, cancer risk discussions, pregnancy planning.
• Past exposure: what you’ve already tried and whether it worked (or stopped working).
• Insurance: formularies and prior authorization can influence the “first pick.”

What to do before starting a biologic (the unglamorousbut importantprep)

Starting a biologic is usually a process, not a single click. Before the first dose, your care team typically checks:

Baseline screening

• Tuberculosis (TB) testing (blood test and sometimes imaging)
• Hepatitis B screening (and sometimes other viral screening based on risk)
• Baseline labs (CBC, liver tests, inflammatory markers as appropriate)

Vaccines and prevention planning

Many vaccines are safest and most effective before immune-suppressing therapy begins. Your clinician may review routine
immunizations (flu, COVID-19, shingles, pneumococcal, and others depending on age and risk) and discuss timingespecially
for live vaccines, which are generally avoided in significantly immunosuppressed states.

Setting expectations

Biologics don’t always work instantly. Depending on the medication and severity, you might see improvements within weeks,
but full benefit can take longer. The plan should include what “success” looks like and when to reassess.

How you’ll know it’s working: treat-to-target in plain English

The days of “If you feel better, we’re done here” are fading. Treat-to-target means tracking:

• Symptoms: bleeding, urgency, stool frequency, nighttime symptoms, energy.
• Biomarkers: blood inflammation markers and/or fecal calprotectin (a stool test often used to reflect gut inflammation).
• Endoscopy: checking the lining of the colon for healing when appropriate.

Your doctor might say something like: “Let’s give this therapy a fair trial, then evaluate.” That “fair trial” includes
time for induction dosing and a realistic window for responseplus a plan B if the response is partial.

Safety: what to watch for (without spiraling)

All advanced therapies have risks, and your GI team should walk you through them. In broad strokes, biologics may increase
susceptibility to infections. You’ll usually be told to contact your clinician if you develop fevers, persistent cough,
unusual sores, or signs of infection.

Common practical safety topics

• Infections: especially if you’re around sick contacts often.
• Skin checks: depending on therapy and personal risk factors.
• Infusion or injection reactions: usually manageable, but worth knowing the signs.
• Medication interactions: including other immune suppressants.

One more reassuring point: biologics are used widely in IBD, and clinicians have established protocols for screening and
monitoring. The goal is informed cautionnot fear.

Cost and access: the part nobody wants to talk about (but everyone has to)

Biologics can be expensive, and insurance approvals can feel like a side quest you didn’t sign up for. Two helpful facts:

• Patient assistance programs may lower out-of-pocket costs for eligible patients.
• Biosimilars (especially for anti-TNFs like infliximab and adalimumab) can expand access and reduce cost.

If you’re stuck in prior-authorization limbo, ask your clinic whether they have an IBD navigator, specialty pharmacy team,
or infusion coordinator. This paperwork jungle is sadly normaland also navigable with help.

When it’s time to switch biologics (or change strategy)

Sometimes a biologic works beautifullyuntil it doesn’t. Loss of response can happen because the disease adapts, drug levels
are too low, or antibodies develop (more common with certain biologics).

Typical next steps your GI might consider

• Optimizing the current biologic (dose/interval adjustment)
• Checking drug levels and antibodies (therapeutic drug monitoring) when appropriate
• Switching within the same class (e.g., one anti-TNF to another)
• Switching to a different mechanism (e.g., anti-TNF → vedolizumab or IL-pathway biologic)

The “expert” move is not pretending a half-working plan is good enough. The expert move is measuring, adapting, and aiming
for remission you can actually live in.

When surgery enters the conversation

Biologics are often used to avoid complications and reduce the chance of colectomy, but surgery can be a healthy, curative
option for UC in certain situationsespecially if medical therapy can’t control disease or complications arise.

If surgery is mentioned, it doesn’t mean you’ve “lost.” It means your care team is considering every option to keep you
safe and restore quality of life. Many patients do extremely well with surgical approaches when needed.

Quick questions patients ask (and experts answer)

“Is it too early to start biologics?”

If you have moderate to severe disease, repeated steroid use, significant inflammation on scope, or high-risk features,
it may actually be the right time. Earlier control can mean fewer flares and less long-term damage.

“What if I’m nervous about suppressing my immune system?”

Totally normal. Ask about gut-selective options, your personal infection risk, vaccine planning, and monitoring strategy.
Most biologic decisions are individualizednot one-size-fits-all.

“How long will I need to stay on a biologic?”

Many people stay on effective therapy long-term to maintain remission. Stopping can increase relapse risk, so discontinuation
is usually a carefully planned decisionif it’s considered at all.

Real-World Experiences: What Patients Wish They’d Known (About )

If you ask patients what it’s like to start a biologic, you’ll rarely hear, “Ah yes, the pharmacology was delightful.”
You’ll hear about logistics, emotions, and the weirdly personal relationship you develop with appointment calendars.
Here are common real-world experiencesshared as themes and composite examplesnot as a substitute for your own medical advice.

The mental shift can be bigger than the needle. Many people spend months (or years) trying to “earn” the
right to feel better: changing diets, timing meds perfectly, hoping the flare is “just stress.” Starting a biologic often
marks a turning point: “Okay, we’re treating the disease like it deserves to be treated.” Patients frequently describe
relief… mixed with nerves. Relief because there’s finally a plan. Nerves because the plan has a serious-sounding name.
Both feelings can be true at once.

Infusion day is surprisingly boringin a good way. People imagine dramatic hospital vibes. In reality,
many infusion centers look like quiet lounges where the biggest threat is running out of phone battery. Patients bring
headphones, snacks, a book, and sometimes a small army of chargers. The first infusion can feel intimidating; the third
one often feels like a routine coffee run (minus the coffee, depending on your colon’s mood).

Insurance is the villain nobody cast, but here we are. A common frustration is delays: prior authorizations,
step-therapy requirements, specialty pharmacies calling at inconvenient times, and the classic “we sent the form” ping-pong.
Patients who do best often recruit help earlyasking the GI office who handles authorizations, whether there’s a nurse
navigator, and what patient assistance programs exist. It’s not fair that you need project-management skills to access
healthcare, but using them can speed things up.

Response can be gradualand that’s emotionally tricky. Some people feel better quickly: less bleeding, fewer
urgent sprints, more energy. Others improve in steps: week two is slightly better, week six is clearly better, week twelve
is when they realize they stopped mapping bathrooms everywhere they go. In clinic, one of the most helpful reframes is:
“We’re looking for a trend, not a miracle.” Tracking symptoms in a simple note (stool frequency, bleeding, urgency, sleep)
helps you see progress when your brain is still bracing for disaster.

Life planning gets easier when flares stop running the schedule. Patients often report the biggest win isn’t
just fewer symptomsit’s freedom: saying yes to travel, dinners out, long meetings, and workouts without fear. A biologic
that works well can feel like someone quietly gave you your calendar back.

The best experience is a partnership. People who feel most confident tend to have a clear plan:
what we’re targeting, how we’ll measure it, when we’ll reassess, and what we’ll do if the response is partial. If you can
leave appointments knowing the “why,” the “when,” and the “what next,” you’re not just taking a biologicyou’re running a
smarter strategy.